GE HealthCare (NASDAQ: GEHC) Faces Market Perform Rating Amidst Securities Investigation and Innovation Efforts

Font: Financial Modeling Prep  • Jul 08, 2026

• BMO Capital's "Market Perform" Rating: Analyst firm BMO Capital initiated coverage on GE HealthCare with a "Market Perform" rating, suggesting the stock is expected to align with overall market performance.
• Securities Fraud Investigation: The company is currently under a securities fraud investigation by Glancy Prongay Wolke & Rotter LLP, concerning potential violations of federal securities laws.
• Revised EPS Guidance & Innovation: Following Q1 2026 results, GE HealthCare lowered its full-year adjusted EPS guidance, yet continues to pursue innovation through a new research collaboration with Mayo Clinic for cancer treatment.

GE HealthCare (NASDAQ: GEHC) is a global medical technology and diagnostics company with a market capitalization of approximately $29.42 billion. On July 8, 2026, the analyst firm BMO Capital initiated coverage on GE HealthCare. The firm assigned the stock a "Market Perform" rating, which suggests it is expected to perform in line with the overall market.

At the time of the rating, the stock price was $64.68. This neutral outlook comes as the company faces an ongoing securities fraud investigation, as highlighted by PR Newswire. The inquiry by law firm Glancy Prongay Wolke & Rotter LLP concerns possible violations of federal securities laws on behalf of investors who lost money.

The investigation follows GE HealthCare's first-quarter 2026 results. The company lowered its full-year 2026 adjusted earnings per share (EPS) guidance to a range of $4.80 to $5.00. EPS is a measure of a company's profit for each share of stock, and a lower forecast can signal challenges ahead for profitability.

Management attributed the weaker profit performance to a recall associated with a supplier. Despite this, GE HealthCare is moving forward with innovation. As highlighted by Business Wire, the company announced a new research collaboration with Mayo Clinic. This partnership aims to advance personalized cancer treatment through a novel theranostics study.

Investors are also awaiting the company's next financial report. GE HealthCare is scheduled to release its second-quarter 2026 financial results on July 29, 2026. A conference call with management will follow to discuss the performance and provide further details on the company's outlook.